SHP2: A new target for pro-senescence cancer therapies

EMBO Journal

Volumn 34, Issue 11, 2015, Pages 1439-1441

  Serrano, Manuel ^a  

^a Centro Nacional de Investigations Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR 1; CXCL1 CHEMOKINE; CXCL2 CHEMOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; NOTCH RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ARTICLE; BREAST CANCER; CANCER CELL; CELL AGING; CELL PROLIFERATION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; ANIMAL; ENZYMOLOGY; EXPERIMENTAL MAMMARY NEOPLASM; FEMALE; METABOLISM;

ANIMALS; CELL AGING; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 84931566227     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.15252/embj.201591616     Document Type: Article

References (10)

1. Aceto N, Sausgruber N, Brinkhaus H, Gaidatzis D, Martiny-Baron G, Mazzarol G, Confalonieri S, Quarto M, Hu G, Balwierz PJ, Pachkov M, Elledge SJ, van Nimwegen E, Stadler MB, Bentires-Alj M, (2012) Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop. Nat Med 18: 529-537
2. Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T, (2014) MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance. Curr Drug Targets 15: 114-123
3. Butterworth S, Overduin M, Barr AJ, (2014) Targeting protein tyrosine phosphatase SHP2 for therapeutic intervention. Future Med Chem 6: 1423-1437
4. Demaria M, Ohtani N, Youssef SA, Rodier F, Toussaint W, Mitchell JR, Laberge RM, Vijg J, Van Steeg H, Dolle ME, Hoeijmakers JH, de Bruin A, Hara E, Campisi J, (2014) An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 31: 722-733
5. Dickson MA, (2014) Molecular pathways: CDK4 inhibitors for cancer therapy. Clin Cancer Res 20: 3379-3383
6. Lan L, Holland JD, Qi J, Grosskopf S, Vogel R, Gyorffy B, Wulf-Goldenberg A, Birchmeier W, (2015) Shp2 signaling suppresses senescence in PyMT-induced mammary gland cancer in mice. EMBO J 34: 1493-1508
7. Li J, Kang Y, Wei L, Liu W, Tian Y, Chen B, Lin X, Li Y, Feng GS, Lu Z, (2014) Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor. PLoS ONE 9: e102847
8. Munoz-Espin D, Serrano M, (2014) Cellular senescence: from physiology to pathology. Nat Rev Mol Cell Biol 15: 482-496
9. Toso A, Revandkar A, Di Mitri D, Guccini I, Proietti M, Sarti M, Pinton S, Zhang J, Kalathur M, Civenni G, Jarrossay D, Montani E, Marini C, Garcia-Escudero R, Scanziani E, Grassi F, Pandolfi PP, Catapano CV, Alimonti A, (2014) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep 9: 75-89
10. Zhou X, Coad J, Ducatman B, Agazie YM, (2008) SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology 53: 389-402